-
FDA approves Bayer's Nexavar for thyroid cancer
SILVER SPRING, Md. – The Food and Drug Administration has approved a drug made by Bayer HealthCare Pharmaceuticals for treating thyroid cancer, the agency said Friday.
The FDA announced the approval of Nexavar (sorafenib) to treat late-stage differentiated thyroid cancer. The drug was already approved for kidney and liver cancers. The drug works by limiting cancer cell growth and replication by inhibiting proteins within the cells.
-
Greatest phase-2, phase-3 drug R&D activity seen in oncology, report finds
BURLINGTON, Mass. — While drug companies are developing treatments for a wide variety of diseases, the greatest amount of mid- to late-stage research and development activity is in cancer treatments, according to a new report.
According to healthcare market research company Decision Resources, among the top 25 drug companies, oncology is the focus for 30% of phase-2 drugs and 22% of phase-3 drugs. Other areas seeing strong activity include drugs for obesity, diabetes, infections and central nervous system disorders.